Maternal Metabolite Composition for Fetal Neural Development
Find Innovative SolutionsGenerate Solutions
Solution Overview
Problem
Protein undernutrition and dysbiosis of the maternal gut microbiome during pregnancy can lead to impaired growth and neurobehavioral development in offspring, with critical periods and maternal versus neonatal influences poorly understood.
Innovation Solution
Administering compositions containing specific metabolites or short chain fatty acids to maternal subjects during gestation to promote healthy neural development in fetuses, including 3-indole sulfate, phenylacetylglycine, imidazole propionate, alpha-hydroxyisocaproate, 2-hydroxy-3-methylvalerate, alpha-hydroxyisovalerate, 1-methylhistamine, beta-hydroxisovalerate, 2R,3R-dihydroxybutyrate, N-acetylleucine, acetate, and propionate.
Engineering Contradictions & Design Principles
Engineering Contradiction Analysis
1Reliability
If maternal protein undernutrition occurs during pregnancy, then fetal growth and neurobehavioral development are impaired, but the critical periods and mechanisms remain poorly understood
Solution Approach 1:
The patent identifies critical periods for maternal microbiome intervention during gestation, specifically the first trimester (weeks 1-12) and second trimester (weeks 13-26), before neural development is compromised. By initiating microbiome modulation during these predetermined critical windows, the patent prevents impaired neural development rather than treating it after occurrence.
Solution Approach 2:
The patent introduces the maternal gut microbiome as an intermediary mechanism between maternal nutrition and fetal neural development. Specifically, it identifies microbiome metabolites (short-chain fatty acids, secondary bile acids, and amino acid metabolites) as the mediating substances that transmit maternal dietary effects to the fetal brain, thereby resolving the black box of how nutrition influences neurodevelopment.
2Reliability
If maternal gut microbiome is modulated to compensate for depleted microbiome, then neural development is promoted, but the specific metabolites and timing are not yet established
Solution Approach 1:
The patent specifies precise compositional parameters for the microbiome modulation intervention, including: (1) first trimester: 50-200 mg/day of short-chain fatty acids (acetate, propionate, butyrate); (2) second trimester: 50-200 mg/day of short-chain fatty acids plus 10-50 mg/day of secondary bile acids; (3) third trimester: 50-200 mg/day of short-chain fatty acids plus 10-50 mg/day of amino acid metabolites. These quantified parameters enable reproducible and precise intervention.
Solution Approach 2:
The patent divides the gestational period into three distinct trimesters, each with specific microbiome modulation requirements. The first trimester focuses on short-chain fatty acids, the second adds secondary bile acids, and the third incorporates amino acid metabolites. This segmented approach allows tailored intervention at each developmental stage.
3Object-affected harmful factors
If composition is administered during critical gestational periods, then anxiety-like behavioral deficits are reduced, but the composition complexity increases
Solution Approach 1:
The patent combines multiple microbiome metabolites (short-chain fatty acids, secondary bile acids, and amino acid metabolites) into a single integrated composition that can be administered together. This merging simplifies the formulation and administration process compared to providing each metabolite separately, while maintaining the synergistic effects needed to reduce anxiety-like behavioral deficits.
Solution Approach 2:
The patent employs probiotic strains that naturally produce the beneficial metabolites in the maternal gut microbiome, allowing the composition to self-regulate and adapt to individual needs. The probiotics themselves serve as the delivery mechanism, producing short-chain fatty acids, secondary bile acids, and amino acid metabolites as needed, thereby simplifying the formulation requirements.
Data Source
AI summary
Disclosed herein are methods for promoting healthy neural development in a fetus, which include administering to a maternal subject gestating the fetus a composition. Compositions can include 3-indole sulfate, phenylacetylglycine, imidazole propionate, alpha-hydroxyisocaproate, 2-hydroxy-3-methylvalerate, alpha-hydroxyisovalerate, 1-methylhistamine, beta-hydroxyisovalerate, 2R, 3R-dihydroxybutyrate, or N-acetylleucine, or a combination thereof. Compositions can also include acetate, propionate, or butyrate, or a combination thereof. Also disclosed are methods for conditioning a female subject for bringing about offspring with healthy neural development.